VG081821AC

VG081821AC is a novel, potent, and selective small molecule antagonist of the adenosine A2A receptor (A2AR), developed by Vimgreen Pharmaceuticals for the treatment of Parkinson’s disease. Uniquely, it acts not only as an A2A receptor antagonist but also as a highly potent inverse agonist at this receptor. This dual mechanism may provide both symptomatic relief and potential disease-modifying benefits in Parkinson’s disease by improving motor symptoms and possibly delaying or reducing motor complications associated with long-term dopaminergic therapy. Unlike traditional dopamine replacement therapies such as L-Dopa—which are effective but often lead to complications over time—VG081821AC offers a non-dopaminergic approach that can be used as monotherapy in early-to-mid stage PD or later combined with low-dose L-Dopa to minimize side effects. The drug is currently being evaluated in Phase 2 clinical trials for its efficacy and safety in early-to-mid stage Parkinson's disease patients[2][5][6][8].